NASDAQ:ACOR Acorda Therapeutics (ACOR) Stock Price, News & Analysis → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free ACOR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.66▼$15.6052-Week Range N/AVolume416,900 shsAverage Volume119,299 shsMarket Capitalization$820,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Acorda Therapeutics alerts: Email Address Ad Monetary GoldDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. About Acorda Therapeutics Stock (NASDAQ:ACOR)Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Read More Ad Monetary GoldDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. ACOR Stock News HeadlinesMay 16 at 8:35 PM | msn.comEssential cancer treatment company files Chapter 11 bankruptcyMay 14 at 3:21 AM | americanbankingnews.comAcorda Therapeutics (NASDAQ:ACOR) Now Covered by Analysts at StockNews.comApril 15, 2024 | businesswire.comAcorda Therapeutics Announces Delisting from NasdaqApril 14, 2024 | wsj.comAcorda Therapeutics Inc.April 8, 2024 | msn.comPearl River-based Acorda Therapeutics to close; 97 jobs impactedApril 6, 2024 | finance.yahoo.comRiskiest Junk Bonds Shunned in Europe on Rising Risk of DefaultApril 3, 2024 | businesswire.comAcorda Therapeutics Announces Nasdaq Delisting NotificationApril 3, 2024 | baystreet.caAcorda Therapeutics Files for Chapter 11 BankruptcyApril 2, 2024 | msn.comCrude Oil Surges Over 1%; US Factory Orders Increase In FebruaryApril 2, 2024 | benzinga.comWhy Acorda Therapeutics Stock Is Down Nearly 90%April 2, 2024 | investorplace.comWhy Is Acorda Therapeutics (ACOR) Stock Down 72% Today?April 2, 2024 | morningstar.comNorth American Morning Briefing: Stocks Seen Weaker as Doubts Over Fed Cuts MountApril 2, 2024 | finanznachrichten.deMerz Therapeutics: Merz Enters Asset Purchase Agreement With a US-Based Biotech CompanyApril 1, 2024 | msn.comAcorda retires from PNP after 3 months of extended serviceApril 1, 2024 | msn.comRetired PNP chief Acorda: I did my bestApril 1, 2024 | marketwatch.comStocks to Watch: PVH, Canoo, Acorda TherapeuticsApril 1, 2024 | msn.comAcorda Therapeutics shares sink nearly 40% after bankruptcy filingApril 1, 2024 | finance.yahoo.comAcorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024March 26, 2024 | finance.yahoo.comAcorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024March 11, 2024 | finance.yahoo.comKlick Health Launches First AI Social Media Comment Moderator for Life Sciences IndustryFebruary 28, 2024 | stocknews.com3 Biotech Stocks to Watch in March for SuccessFebruary 23, 2024 | benzinga.comAcorda Therapeutics Stock (NASDAQ:ACOR), Short Interest ReportFebruary 22, 2024 | benzinga.comAcorda Therapeutics Stock (NASDAQ:ACOR) Dividends: History, Yield and DatesFebruary 20, 2024 | msn.comAcorda: No policy vs. TikTok use in PNPFebruary 6, 2024 | msn.comAcorda: PNP can’t interfere with people’s initiative for Charter changeSee More Headlines Receive ACOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:ACOR CUSIP00484M10 CIK1008848 Webwww.acorda.com Phone(914) 347-4300Fax914-347-4560Employees111Year Founded1995Profitability EPS (Most Recent Fiscal Year)($203.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-252,850,000.00 Net Margins-214.95% Pretax Margin-251.65% Return on Equity-2,206.93% Return on Assets-83.28% Debt Debt-to-Equity Ratio3.07 Current Ratio0.33 Quick Ratio0.26 Sales & Book Value Annual Sales$117.63 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.02 Book Value($127.17) per share Price / BookN/AMiscellaneous Outstanding Shares1,240,000Free Float1,210,000Market Cap$820,000.00 OptionableNo Data Beta1.40 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Ron Cohen M.D. (Age 68)Founder, CEO, President & Director Comp: $984.15kMr. Michael A. Gesser M.B.A. (Age 61)Chief Financial Officer Comp: $459.15kMr. Kerry M. Clem (Age 54)Chief Commercial Officer Comp: $592.23kMr. Robert Morales (Age 56)Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller Ms. Felicia VonellaVice President of Investor RelationsMr. Neil S. Belloff Esq. (Age 64)General Counsel & Corporate Secretary Ms. Tierney SaccavinoExecutive Vice President of Corporate CommunicationsMs. Denise J. DucaExecutive Vice President of Human ResourcesMr. Andrew Mayer J.D.Senior Vice PresidentSofia AliSenior VP of Operations & Strategic PlanningMore ExecutivesKey CompetitorsScinai ImmunotherapeuticsNASDAQ:SCNISQZ BiotechnologiesNYSE:SQZAcorda TherapeuticsNASDAQ:ACORQWindtree TherapeuticsNASDAQ:WINTGamida CellNASDAQ:GMDAQView All Competitors ACOR Stock Analysis - Frequently Asked Questions How were Acorda Therapeutics' earnings last quarter? Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) earnings per share for the quarter, topping analysts' consensus estimates of ($31.20) by $2.60. The biopharmaceutical company earned $31.46 million during the quarter, compared to analyst estimates of $30.57 million. Acorda Therapeutics had a negative net margin of 214.95% and a negative trailing twelve-month return on equity of 2,206.93%. When did Acorda Therapeutics' stock split? Shares of Acorda Therapeutics reverse split on the morning of Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Ron Cohen's approval rating as Acorda Therapeutics' CEO? 39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acorda Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT). Who are Acorda Therapeutics' major shareholders? Acorda Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. This page (NASDAQ:ACOR) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersHow Biden has already won 2024Porter & CompanyDems have chosen Biden replacement?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge Alerts348 million Americans lives to END as we know it?The Oxford ClubMissed NVDA? Buy this AI stock NOWChaikin AnalyticsDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldA ‘DeFi Summer’ Projected!Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
